To support the growing viral vector sector, Fujifilm says it will invest $40 million in Fujifilm Diosynth Biotechnologies, a CDMO for biologics, viral vaccines, and viral vectors, to establish a new process development and manufacturing facility for viral vectors and advanced therapies.

The new facility, to be located in the greater Boston area, is scheduled to begin process development operations in fall 2021, and contract manufacturing services for early phase clinical trials by fall 2023.

“We are strategically establishing this facility in the greater Boston area where there is a high concentration of biopharmaceutical companies and academia innovating in the field of advanced therapies,” said Martin Meeson, CEO, Fujifilm Diosynth Biotechnologies.

This will be the CDMO’s third viral vector and advanced therapy facility, with other locations in Texas and in the U.K.

“The strength of Fujifilm’s Bio CDMO business lies in its wide-range of capabilities: process development for a variety of biopharmaceutical such as antibodies, recombinant protein, gene therapy, vaccines, oncolytic virus and more, along with flexible facilities that can adapt to small- or large-scale manufacturing of drug substances, formulation and packaging,” noted Takatoshi Ishikawa, senior executive vice president and chief life science officer, Fujifilm.

Previous articleSARS-CoV-2 Genomic Analysis Traces U.K. Transmission Lineages
Next articleSartorius Agrees to Acquire Novasep’s Chromatography Process Equipment Division